US 12,110,334 B2
Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
Stephen L. Nishimura, San Francisco, CA (US); Jianlong Lou, San Francisco, CA (US); James D. Marks, San Francisco, CA (US); Jody L. Baron, San Francisco, CA (US); Yifan Cheng, San Francisco, CA (US); Shenping Wu, San Francisco, CA (US); Anthony Cormier, San Francisco, CA (US); and Naoki Takasaka, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jan. 11, 2023, as Appl. No. 18/153,277.
Application 18/153,277 is a division of application No. 17/155,784, filed on Jan. 22, 2021, granted, now 11,591,402.
Application 17/155,784 is a division of application No. 16/331,902, granted, now 10,954,304, previously published as PCT/US2017/054306, filed on Sep. 29, 2017.
Claims priority of provisional application 62/529,381, filed on Jul. 6, 2017.
Claims priority of provisional application 62/401,570, filed on Sep. 29, 2016.
Prior Publication US 2023/0331851 A1, Oct. 19, 2023
Int. Cl. G01N 33/53 (2006.01); A61P 1/04 (2006.01); A61P 31/20 (2006.01); A61P 35/04 (2006.01); A61P 37/04 (2006.01); C07K 14/705 (2006.01); C07K 16/00 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); G01N 33/563 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2839 (2013.01) [A61P 1/04 (2018.01); A61P 31/20 (2018.01); A61P 35/04 (2018.01); A61P 37/04 (2018.01); C07K 14/705 (2013.01); C07K 16/22 (2013.01); G01N 33/563 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 12 Claims
 
1. An antibody that specifically binds to human αvβ8 and that comprises heavy chain complementarity determining regions (CDRs) SEQ ID NO:299, SEQ ID NO:301, and SEQ ID NO:303; and light chain CDRs SEQ ID NO:307, SEQ ID NO:309, and SEQ ID NO:311.